Current Report Filing (8-k)
September 10 2020 - 4:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2020
SATSUMA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39041
|
|
81-3039831
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 410-3200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
STSA
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On September 10, 2020, Satsuma Pharmaceuticals, Inc. (Satsuma or the Company) announced the topline results from its
Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal) powder as an acute treatment for migraine. There was no statistically significant difference between either dosage strength of STS101 (3.9 mg and 5.2 mg) and
placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration. Further analysis of EMERGE trial data is ongoing, and Satsuma expects to provide a more
detailed update on its business plans after these analyses are completed.
Forward-Looking Statements
Any statements contained in this Form 8-K regarding matters that are not historical facts are
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied
by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the Companys expectations regarding STS101 and its future business plans. The Companys actual results could differ materially from
those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Companys Quarterly Report on Form 10-Q for the quarter ended
June 30, 2020, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. You should not place undue reliance on these forward-looking statements. All such statements speak
only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SATSUMA PHARMACEUTICALS, INC.
|
|
|
|
|
Date: September 10, 2020
|
|
|
|
By:
|
|
/s/ Thomas ONeil
|
|
|
|
|
|
|
Thomas ONeil
Chief Financial
Officer
|
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Sep 2023 to Sep 2024